KLRK1 and lung carcinoma: Although it was previously reported that 10 μM of Gefitinib upregulated NKG2D ligands in lung cancer cell lines [35], pharmacokinetic analysis showed the serum concentration of Gefitinib reached less than 1 μM in the clinical setting [36].